Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

NervGen Pharma Corp (NGEN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.33 +0.17    +7.87%
03/05 - Closed. Currency in CAD ( Disclaimer )
  • Volume: 261,878
  • Bid/Ask: 2.30 / 2.33
  • Day's Range: 2.18 - 2.35
Type:  Equity
Market:  Canada
NervGen Pharma 2.33 +0.17 +7.87%

NervGen Pharma Corp Company Profile

 
Get an in-depth profile of NervGen Pharma Corp, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Contact Information

Address 112-970 Burrard Street Unit 1290
Vancouver, V6Z 2R4
Canada
Phone 778-731-1711
Fax -

Top Executives

Name Age Since Title
Jerry Silver - - Co-Inventor & Scientific Advisor
Bruce Lamb - 2021 Member of Alzheimer's Disease Scientific Advisory Board
Glenn Antony Ives 60 2021 Independent Director
Brian McAlister - - Co-Founder & Advisor
Martin Rhys Farlow - 2021 Member of Alzheimer's Disease Scientific Advisory Board
Brian Eric Bayley 71 2018 Independent Director
Jeffrey L. Cummings 74 2021 Member of Alzheimer's Disease Scientific Advisory Board
Daniel P. Lammertse - 2021 Member of Clinical Spinal Cord Injury Advisory Board
Adam H. Rogers - 2022 Director
Henrik Zetterberg - 2021 Member of Alzheimer's Disease Scientific Advisory Board
Steven Kirshblum - 2021 Member of Clinical Spinal Cord Injury Advisory Board
Harold Martin Punnett - 2017 Co-Founder & Independent Director
Krista L. McKerracher - 2021 Independent Director
William Joseph Radvak 61 2017 Co-Founder & Chairman
George Perry 71 2021 Member of Alzheimer's Disease Scientific Advisory Board
Robert W. Naismith 79 2021 Multiple Sclerosis Clinical Advisory Board
Michael A. Weiner 77 2021 Member of Alzheimer's Disease Scientific Advisory Board
Jeremy Chataway - 2021 Multiple Sclerosis Clinical Advisory Board
Brian Kwon - 2021 Member of Clinical Spinal Cord Injury Advisory Board
Randall E. Kaye 62 2020 Independent Director
Linda Jones - - Member of Clinical Spinal Cord Injury Advisory Board
Jack Antel - 2021 Multiple Sclerosis Clinical Advisory Board
James Guest - 2021 Member of Clinical Spinal Cord Injury Advisory Board
Michael Davis - 2020 Advisor
Jeffrey K. Cohen - 2021 Multiple Sclerosis Clinical Advisory Board
Michael Kelly 58 2023 CEO, President & Director
Anneke Van Der Walt - 2021 Multiple Sclerosis Clinical Advisory Board
Reisa Sperling - 2021 Member of Alzheimer's Disease Scientific Advisory Board
John Craig Thompson - 2022 Independent Director
John Ruffolo - 2023 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NGEN Comments

Write your thoughts about NervGen Pharma Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email